论文部分内容阅读
目的探讨孟鲁司特钠联合丙卡特罗治疗支原体肺炎并发哮喘急性发作的临床疗效。方法选取盐边县人民医院2014年3月—2016年5月收治的支原体肺炎并发哮喘急性发作患儿166例,随机分为对照组和研究组,各83例。患儿入院后均给予常规对症治疗,对照组患儿给予丙卡特罗+酮替芬干预治疗,研究组患儿给予丙卡特罗+孟鲁司特钠干预治疗。比较两组患儿的临床疗效,治疗前后基质金属蛋白酶9(MMP-9)、组织基质金属蛋白酶抑制剂1(TIMP-1)、MMP-9/TIMP-1的变化情况及不良反应发生情况。结果研究组患儿临床疗效优于对照组(P<0.05)。治疗前,两组患儿MMP-9、TIMP-1、MMP-9/TIMP-1比较,差异无统计学意义(P>0.05);治疗后,研究组患儿MMP-9、MMP-9/TIMP-1低于对照组,TIMP-1高于对照组(P<0.05)。两组患儿均未出现严重不良反应。结论采用孟鲁司特钠联合丙卡特罗治疗小儿支原体肺炎并发哮喘急性发作的临床疗效确切,可有效改善气道炎性反应,且安全性好。
Objective To investigate the clinical efficacy of montelukast sodium and procaterol in the treatment of mycoplasmal pneumonia complicated by acute attack of asthma. Methods A total of 166 children with mycoplasmal pneumonia complicated with acute asthma who were treated in Yanbian People’s Hospital from March 2014 to May 2016 were randomly divided into control group and study group, with 83 cases in each group. Children admitted to hospital were given conventional symptomatic treatment, the control group given procaterol ketotifen intervention, the study group given procaterol montelukast sodium intervention. The clinical efficacy of the two groups were compared. The changes of MMP-9, TIMP-1, MMP-9 / TIMP-1 and the incidence of adverse reactions before and after treatment were compared. Results The clinical efficacy of study group was better than that of control group (P <0.05). There was no significant difference in MMP-9, TIMP-1 and MMP-9 / TIMP-1 between the two groups before treatment (P> 0.05) TIMP-1 was lower than the control group, TIMP-1 was higher than the control group (P <0.05). Two groups of children did not appear serious adverse reactions. Conclusion The combination of montelukast sodium and procaterol for the treatment of mycoplasma pneumonia complicated by acute attack of asthma has definite curative effect and can effectively improve the airway inflammatory response with good safety.